AksharChem India Q4 FY26 Results: PAT Rs 5 Cr

AksharChem India Q4 FY26 results were declared on May 21, 2026. The company reported PAT of Rs 5 crore for the quarter ended March 31, 2026, up 400.0% YoY compared to Rs 1 crore in Q4 FY25. Revenue from operations stood at Rs 106 crore, up 16.0% YoY. Results are on a Standalone basis. AksharChem India is a Specialty Chemicals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

AksharChem India Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	106	91	+16.0%
Gross Profit	Rs 1 crore	3	-66.0%
Net Profit	5	1	+400.0%
Basis	Standalone

Note: AksharChem India Q4 FY26 results declared May 21, 2026. Verify from BSE/NSE audited filings before investment decisions.

AksharChem India Q4 FY26 Performance Analysis

The AksharChem India Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter. Strong PAT growth of 400% YoY to Rs 5 crore demonstrates significant earnings improvement. AksharChem India operates in the Specialty Chemicals sector, which benefited from India’s GDP growth above 6.5% in FY26.

Revenue grew 16% YoY to Rs 106 crore, driven by strong demand and business expansion.

Screen the best stocks on the Univest Screener.

Key Factors Driving AksharChem India Q4 FY26 Results

Revenue and Business Performance

AksharChem India Q4 FY26 revenue of Rs 106 crore was up 16.0% YoY. Revenue momentum reflects steady demand in the Specialty Chemicals business.

Profitability and Margins

the business PAT of Rs 5 crore up 400.0% YoY. The strong PAT growth demonstrates improving operational leverage and cost discipline.

India Macro Backdrop

The January to March 2026 quarter benefited from India’s GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore for FY27, and resilient domestic consumption. RBI’s accommodative stance supported credit and demand conditions. The Specialty Chemicals sector saw strong tailwinds during this period.

FY27 Outlook

Following the firm results, management commentary on FY27 revenue guidance, margin expansion roadmap, and capital allocation will be key investor watchpoints. The Specialty Chemicals sector continues to benefit from India’s long-term structural growth.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company